Medical Device | June 05, 2026
Omnix Medical advances first-in-class antimicrobial OMN6 into Phase II trials
Targeting deadly drug-resistant acinetobacter infections
Targeting deadly drug-resistant acinetobacter infections
DCGI-approved semaglutide syringes for diabetes and obesity expand treatment choices and improve affordability
At the center of the project is a new cosmetics line developed through collaboration between industry and medicine
Novel fluorescent nanosensor enables real-time detection of indole-3-propionic acid (IPA), paving the way for faster gut health screening, point-of-care diagnostics, and wearable monitoring devices
An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary
The safety profile was described as manageable, though not without notable toxicities
The trial results are for the pharma powerhouse's RET-targeted therapy Retevmo (selpercatinib)
Fertility platform launches flagship clinic with advanced IVF tech
The approval is supported by results from the Phase 3 SWOG 1826 trial
Approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device
Subscribe To Our Newsletter & Stay Updated
